Novo Nordisk (NVO)
(Delayed Data from NYSE)
$118.01 USD
-1.06 (-0.89%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $117.96 -0.05 (-0.04%) 7:58 PM ET
4-Sell of 5 4
C Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$118.01 USD
-1.06 (-0.89%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $117.96 -0.05 (-0.04%) 7:58 PM ET
4-Sell of 5 4
C Value B Growth A Momentum B VGM
Zacks News
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Sweta Killa
Sector ETF report for PPH
Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split
by Kinjel Shah
Merck (MRK), Bristol Myers (BMY), Sanofi (SNY), Glaxo (GSK) and Novo Nordisk (NVO) announce Q4 results.
Novo Nordisk (NVO) Q4 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
Novo Nordisk (NVO) posts in-line earnings, while revenues beat estimates in the fourth quarter of 2019.
SNY vs. NVO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
SNY vs. NVO: Which Stock Is the Better Value Option?
Novo Nordisk's Ozempic Gets FDA Nod for CV Risk Reduction
by Zacks Equity Research
Novo Nordisk's (NVO) Ozempic gets FDA approval for reducing the risk of major adverse cardiovascular events in people with type II diabetes and established CVD.
Lilly to Launch Cheaper Versions of Humalog KwikPen Insulins
by Zacks Equity Research
Eli Lilly (LLY) announced plans to launch cheaper version of its Humalog insulins, Mix75/25 KwikPen and Junior KwikPen.
Novo Nordisk's Shares Up in a Year on Pipeline Progress
by Zacks Equity Research
Novo Nordisk's (NVO) shares have gained in the past year as it makes significant progress in pipeline development.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Sweta Killa
Sector ETF report for PPH
Gilead (GILD) Announces Top-Line Results From NASH Study
by Zacks Equity Research
Gilead's (GILD) mid-stage study on combination and monotherapy investigational treatments for advanced fibrosis due to NASH fails to meet the primary endpoint.
Top Research Reports for Microsoft, Wells Fargo & Chevron
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Wells Fargo (WFC) and Chevron (CVX).
Novo Nordisk Inks Deal With Dicerna to Develop RNAi Therapies
by Zacks Equity Research
Novo Nordisk (NVO) inks deal with Dicerna Pharmaceuticals to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases.
Here's Why AstraZeneca's (AZN) Shares Are Up Year to Date
by Zacks Equity Research
AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us take a look at the reasons for the same.
AstraZeneca/Merck's Selumetinib NDA Gets FDA Priority Status
by Zacks Equity Research
The FDA grants priority review to AstraZeneca (AZN) and Merck's NDA for MEK 1/2 inhibitor, selumetinib. Additionally, Qtrilmet tablets to treat type-II diabetes get approval in the EU.
4 Big Drugmakers to Bet on After a Great Earnings Season
by Kinjel Shah
Big drugmakers post better-than-expected Q3 results, leading to rise in share price of most of the companies in the industry.
The Zacks Analyst Blog Highlights: Microsoft, Novartis, Novo Nordisk, Tesla and General Dynamics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Novartis, Novo Nordisk, Tesla and General Dynamics
FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes
by Zacks Equity Research
Eli Lilly (LLY) gets an unfavorable FDA panel vote to expand the label of its type II diabetes medicine Jardiance (2.5 mg) for type I diabetes.
Top Analyst Reports for Microsoft, Novartis & Novo Nordisk
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Novartis (NVS) and Novo Nordisk (NVO).
The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J
Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products
by Kinjel Shah
Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.
Novo Nordisk (NVO) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Novo Nordisk (NVO) beats earnings estimates but misses sales estimates in the third quarter of 2019.
The Zacks Analyst Blog Highlights: Citigroup, Novo Nordisk, BP, salesforce.com and TC Energy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Citigroup, Novo Nordisk, BP, salesforce.com and TC Energy
Top Analyst Reports for Citigroup, Novo Nordisk & BP
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Citigroup (C), Novo Nordisk (NVO) and BP (BP).
PFE vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
PFE vs. NVO: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Intel, Oracle, Novo Nordisk, ConocoPhillips and Advanced Micro Devices
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intel, Oracle, Novo Nordisk, ConocoPhillips and Advanced Micro Devices
Top Analyst Reports for Intel, Oracle & Novo Nordisk
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Intel (INTC), Oracle (ORCL) and Novo Nordisk (NVO).